Article
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Fecha
2020Registro en:
LANDOVITZ, Raphael J. et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. The lancet HIV, v. 7, n. 7, p. 472-481, 2020.
2405-4704
10.1016/S2352-3018(20)30106-5
Autor
Landovitz, Raphael J.
Li, Sue
Eron Jr., Joseph J.
Grinsztejn, Beatriz
Dawood, Halima
Liu, Albert Y.
Magnus, Manya
Hosseinipour, Mina C.
Panchia, Ravindre
Cottle, Leslie
Chau, Gordon
Richardson, Paul
Marzinke, Mark A.
Eshleman, Susan H.
Kofron, Ryan
Adeyeye, Adeola
Burns, David
Rinehart, Alex R.
Margolis, David
Cohen, Myron S.
McCauley, Marybeth
Hendrix, Craig W.